News

Sweden-based specialty pharmaceutical company Pharmalink has completed its open Phase II trial evaluating the efficacy and safety of Nefecon in IgA nephropathy, a glomerulonephritis leading to end-stage renal

Oxford BioMedica will receive an upfront payment of $26 million and committed funding of up to a further $24 million over three years. In addition, Sanofi-Aventis has an

Belgium-based biopharmaceutical and specialty chemical company UCB has reported top-line results from two Phase III clinical studies to assess the efficacy and safety of brivaracetam as adjunctive treatment

Shoppers Drug Mart has reported that its net earnings for the first quarter ended March 28, 2009 increased 6.1% to C$107m or C$0.49 per diluted share, compared to

Sciele Pharma, a Shiongi Company, and Plethora Solutions have reported promising results from a European Phase III randomized, double-blind, placebo-controlled study of PSD502 for the treatment of premature

Pfizer has reported a net income of $2.73 billion, or $0.40 diluted earnings per share for the first quarter of 2009, a decline of 2%, compared to $2.78

Accordingly the company is no longer relying on the previously announced R&D test data and results. Sequenom has not changed its plans to develop in parallel its RNA-

Portuguese pharmaceutical company Bial-Portela & CA, and Eisai Europe Limited, the European subsidiary of Eisai Co, have reported that the novel once daily anti-epileptic Zebinix has received marketing

This design will enable patients to mix and administer exenatide once weekly from a pre-filled pen device, instead of the syringe and vial currently used in clinical trials,